Project summary description
Influenza virus infections affect millions of people worldwide every year and cause serious mortality.
Current treatment options are limited to viral strain-specific vaccination and are problematic due to antiviral drug
resistance. There is an urgent need to identify novel host innate immune mechanisms providing broad range
protection against influenza. Bronchial epithelial cells orchestrate an oxidative extracellular antimicrobial system
present in the airway surface liquid consisting of the protein lactoperoxidase (LPO), the thiocyanate anion (SCN-
) and hydrogen peroxide (H2O2). LPO oxidizes SCN- using H2O2 into hypothiocyanite (OSCN-) that has known in
vitro antiviral effects. Dual oxidase 1 (Duox1), an NADPH oxidase highly expressed in bronchial epithelial cells,
is the H2O2 source for the system. Our long-term goal is to determine whether the Duox1/H2O2/LPO/SCN-
antiviral system could be manipulated in influenza infection for therapeutic purposes in human patients. The
objective of this proposal is to determine and characterize the antiviral role of Duox1 and LPO against influenza
in multiple experimental systems. Our preliminary data show that 1) primary bronchial epithelial cells inactivate
several influenza viruses in an Duox1/H2O2/LPO/SCN- -dependent manner, 2) Duox1-deficient mice have
increased mortality and morbidity, impaired viral clearance and leukocyte recruitment following influenza
infection in vivo, and 3) the in vitro influenza-inactivating effect of this mechanism can be enhanced to inhibit
influenza infection. Based on these data, our central hypothesis is that the Duox1/H2O2/LPO/SCN- system
attenuates influenza infection, both in vitro and in vivo, and can be boosted to fight influenza. The rationale for
the proposed research is that there is a need to better understand how powerful the antiviral Duox1/LPO-based
system is and how can it be manipulated for therapeutic purposes. The main hypothesis will be tested in cell-
free, airway epithelial and mouse model systems using a wide range of influenza strains. It is anticipated that
our aims will yield several impactful outcomes including 1) detailed description of the anti-influenza mechanism
of action of the Duox1/H2O2/LPO/SCN- system; 2) determination of the in vivo relevance of Duox1 in fighting a
wide range of influenza strains; and 3) exploring the therapeutic potential of the Duox1/H2O2/LPO/SCN- system
to improve influenza clearance and to diminish associated lung damage. Our innovative work shows that the
Duox1/H2O2/LPO/SCN- system inactivates influenza, and uses a Duox1-deficient mouse strain for in vivo studies.
The significance of the outlined work relies in establishing the relevance of a novel innate immune mechanism
of the airways that can be enhanced to attenuate influenza infections or applied in conjunction with influenza
vaccines to potentially enhance efficacy. In summary, our proposed work will have a positive impact in the fields
of airway epithelial biology and antiviral innate immune responses by identifying Duox1 and LPO, as novel,
crucial weapons of the bronchial epithelium against influenza.
Public Health Relevance Statement
Project narrative
The proposed research is relevant to public health because the discovery and mechanistic
understanding of novel innate immune mechanisms protective against a wide range of influenza
strains is expected to advance our knowledge of pathogenesis in influenza infections and lay
down the ground work for future design of novel therapies aimed at improving the antiviral effect
of the airway epithelium. Thus, the proposed research is important to the mission of the NIH by
developing fundamental knowledge that will help to fight human diseases.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AffectAnimal ModelAnionsAnti-viral AgentsAntibody titer measurementAttenuatedBiological ModelsBiologyBirdsCell-Free SystemCellsCysteineDataEconomic BurdenEnzymesEpithelial CellsFutureGoalsHemagglutininHumanHydrogen PeroxideImmuneImmune systemImpairmentIn VitroInfluenzaInfluenza A virusInfluenza B VirusInfluenza preventionInnate Immune ResponseInterventionKnowledgeLeukocytesLinkLungLung infectionsMeasuresMissionMolecularMolecular Mechanisms of ActionMorbidity - disease rateMouse StrainsMusNADPH OxidaseNatural ImmunityNeuraminidase inhibitorOutcomeOxidasesParticipantPathogenesisPathogenicityPatientsPersonsProteinsPublic HealthPulmonary InflammationPulmonary PathologyResearchResistanceRoleRouteSourceSystemTestingTherapeuticThiocyanatesUnited States National Institutes of HealthVaccinationViralViral Drug ResistanceVirionVirusVirus DiseasesVirus InactivationVirus ReplicationWorkadaptive immune responseadaptive immunityairway epitheliumairway surface liquidanti-influenzaantimicrobialapical membraneattenuationbronchial epitheliumcytokinedesignextracellularfightinghuman diseasehypothiocyaniteimprovedin vitro testingin vivoinfluenza infectioninfluenza virus straininfluenza virus vaccineinfluenzavirusinnate immune mechanismsinnovationlung injurymortalitymouse modelnovelnovel therapeuticsrecruitresponsevirucideweapons
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
004315578
UEI
NMJHD63STRC5
Project Start Date
19-February-2020
Project End Date
31-January-2025
Budget Start Date
01-February-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$377,500
Direct Costs
$250,000
Indirect Costs
$127,500
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$377,500
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI146857-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI146857-05
Patents
No Patents information available for 5R01AI146857-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI146857-05
Clinical Studies
No Clinical Studies information available for 5R01AI146857-05
News and More
Related News Releases
No news release information available for 5R01AI146857-05
History
No Historical information available for 5R01AI146857-05
Similar Projects
No Similar Projects information available for 5R01AI146857-05